Compare Gemini Space Station Inc (GEMI) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gemini Space Station Inc vs Organon & Co. Common Stock — how do they compare? Gemini Space Station Inc trades at $3.83 (market cap $500.46M), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Organon & Co. Common Stock is far larger — about 7.2× Gemini Space Station Inc's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Gemini Space Station Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gemini Space Station Inc for 15 Days and Organon & Co. Common Stock for 0 Days on average.
| GEMI | OGN | |
|---|---|---|
Market Cap | $500.46M | $3.61B |
Volume | 1,680,193 | 1,808,049 |
Sector | Financials | Health |
52-Week High | $22.36 | $13.81 |
52-Week Low | $3.54 | $5.70 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $479.48M | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gemini Space Station (GEMI) trades at $4.10, down 0.24% with bearish technical signals despite recent price surges. The company reported Q2 2026 revenue growth of 37% year-over-year but missed earnings estimates with a net loss of -$517 million. Analyst consensus shows mixed sentiment with a $5.25 price target, while technical indicators show oversold conditions with RSI at 10.68.
The stock faces significant fundamental challenges with negative profit margins and cash burn, though revenue diversification shows promise. Near-term catalysts include SEC regulatory developments for tokenized stocks, but legal risks and persistent losses create substantial downside potential for investors.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
